- Olivier joined Andera Partners in 2006.
- Olivier holds a PhD in molecular microbiology from University of Munich (LMU). During his scientific work he focused on fundamental and applied sciences relating to molecular regulation mechanisms in antibiotic biosynthesis.
- In 1998, Olivier joined Mercer Management Consulting in Munich to work on strategic business projects in the healthcare and other industries, in Europe, the US, and Asia.
- Attracted by the emerging biotechnology industry in continental Europe, Olivier joined 3i’s Munich-based Life Sciences practice in 2000. There, he was responsible for investing and managing Life Sciences portfolio companies in Germany, in both biotechnology and medical devices. In 2004, he moved to Paris and led the Life Sciences Venture Capital activities for 3i in France, were he accompanied several exits in the legacy portfolio and invested in new companies in France and in the US. During his tenure at 3i, Olivier became acquainted with the Life Sciences team of Andera, and decided to join them in 2006 to jointly build up the activity to one of the leading players in Europe.
- Olivier currently serves on the board of SciRhom, Ariceum, FIRE 1, Mineralys, Targed, MMI Microsystems, T-Knife, Arvelle Therapeutics, Allecra Therapeutics, HighLife Medical, MedLumics, Tricares and JenaValve. He was also a board member of Corvidia, Sapiens, Endosense, Novexel and Supersonic Imagine up until their respective acquisitions by large pharmaceutical or medical device companies.
Investments of Olivier
SciRhom
Biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies
Ariceum
Novel medicines for systemic targeted radiotherapy to visualize and treat cancer
FIRE 1
Technology for heart failure patients
Mineralys Therapeutics
Clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension
Targed
Biotechnology company focused on developing improved treatments for thrombotic diseases
T-Knife
Thérapie cellulaire pour le traitement de cancers
Highlife Medical
Valve mitrale
Corvidia Therapeutics
Molécule pour le traitement de l’inflammation chez les patients insuffisants rénaux
Medical Micro Instruments
Dispositif robotique pour des opérations de microchirurgie
MedLumics
Nouvelle génération de cathéter d'ablation pour le traitement de l'arythmie cardiaque
Allecra
Agents anti-infectieux contre les bactéries multi-résistantes
JenaValve
Technologie percutanée de remplacement de valves aortiques
Arvelle
Small molecule for the treatment of pharmacoresistant partial epilepsy
Sapiens
Deep brain stimulation system for the treatment of Parkinson’s disease
Endosense
Force-sensing ablation catheters for the treatment of cardiac arrhythmias
SuperSonic Imagine
Ultrasound technology measuring tissue elasticity for cancer detection
Vivoryon
Development of innovative molecule drugs for the treatment of neurodegenerative diseases
Allecra
Development of novel treatments to combat multi drug-resistant bacterial infections
The team andera Life Sciences
Raphaël Wisniewski
Partner
Olivier Litzka
Partner
Sofia Ioannidou
Partner
Jan Van den Bossche
Partner
Aneta Sottil
Partner
Mathieu Piéronne
Director
Yuexin Yu
Director
Natali Romero Barrios
Investment Manager
Yanis Feraoun
Analyst
Elyes Chouaieb
Investment Director
Loan Hoang-Sayag
Venture Partner
Florian Gerard-Mercier
Investment Manager
Thierry Hercend
Venture Partner
Armelle Okoye
Middle Office
Raymond W. Cohen
Venture Advisor
Vanessa Bonvalot
Executive Assistant